What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins

EBioMedicine

Volumn 8, Issue , 2016, Pages 277-290

  Vanderven, Hillary A ^a   Ana Sosa Batiz, Fernanda ^a   Jegaskanda, Sinthujan ^a   Rockman, Steven ^a,b   Laurie, Karen ^a   Barr, Ian ^a   Chen, Weisan ^c   Wines, Bruce ^d   Hogarth, P Mark ^d   Lambe, Teresa ^e   Gilbert, Sarah C ^e   Parsons, Matthew S ^a   Kent, Stephen J ^a,f,g  

^a PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY   (Australia)

^b Seqirus Ltd   (Australia)

^c LA TROBE UNIVERSITY   (Australia)

^d BURNET INSTITUTE   (Australia)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f MONASH UNIVERSITY   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antibody dependent cellular cytotoxicity; Hemagglutinin; Influenza; Matrix protein 1; Natural killer cells; Nucleoprotein

Indexed keywords

GAMMA INTERFERON; HEMAGGLUTININ; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MATRIX PROTEIN; VIRUS NUCLEOPROTEIN; FC RECEPTOR; FCGR3A PROTEIN, HUMAN; INFLUENZA VIRUS HEMAGGLUTININ; PROTEIN BINDING; VIRAL PROTEIN; VIRUS ANTIBODY;

ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BLOOD SAMPLING; CELL ACTIVATION; CELLULAR IMMUNITY; COMPLEMENT FIXATION TEST; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEMAGGLUTINATION INHIBITION TEST; HUMAN; INFLUENZA VIRUS; MIDDLE AGED; NATURAL KILLER CELL; PRIORITY JOURNAL; SEROCONVERSION; VIRUS INFECTION; VIRUS SHEDDING; YOUNG ADULT; CASE CONTROL STUDY; CELL LINE; CHEMISTRY; IMMUNOLOGY; INFLUENZA, HUMAN; LYMPHOCYTE ACTIVATION; METABOLISM; ORTHOMYXOVIRIDAE; PROTEIN MULTIMERIZATION; SEVERITY OF ILLNESS INDEX; VIROLOGY; VIRUS LOAD;

ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CASE-CONTROL STUDIES; CELL LINE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA, HUMAN; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; ORTHOMYXOVIRIDAE; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RECEPTORS, IGG; SEVERITY OF ILLNESS INDEX; VIRAL LOAD; VIRAL PROTEINS; VIRUS SHEDDING;

EID: 84970016409     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.04.029     Document Type: Article

References (68)

1. Arnold J.N., Wormald M.R., Sim R.B., Rudd P.M., Dwek R.A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 2007, 25:21-50.
2. Atmar R.L., Keitel W.A., Cate T.R., Munoz F.M., Ruben F., Couch R.B. A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine 2007, 25:5367-5373.
3. Bodewes R., Geelhoed-Mieras M.M., Wrammert J., et al. In vitro assessment of the immunological significance of a human monoclonal antibody directed to the influenza a virus nucleoprotein. Clin. Vaccine Immunol. 2013, 20:1333-1337.
4. Carragher D.M., Kaminski D.A., Moquin A., Hartson L., Randall T.D. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J. Immunol. 2008, 181:4168-4176.
5. Chen L., Zanker D., Xiao K., Wu C., Zou Q., Chen W. Immunodominant CD4+ T-cell responses to influenza A virus in healthy individuals focus on matrix 1 and nucleoprotein. J. Virol. 2014, 88:11760-11773.
6. Cox J.H. HIV-1-specific antibody-dependent cellular cytotoxicity (ADCC). Methods Mol. Med. 1999, 17:373-381.
7. DiLillo D.J., Tan G.S., Palese P., Ravetch J.V. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat. Med. 2014, 20:143-151.
8. El Bakkouri K., Descamps F., De Filette M., et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 2011, 186:1022-1031.
9. Ellebedy A.H., Krammer F., Li G.M., et al. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:13133-13138.
10. Ennis F.A., Yi-Hua Q., Schild G.C. Antibody and cytotoxic T lymphocyte responses of humans to live and inactivated influenza vaccines. J. Gen. Virol. 1982, 58:273-281.
11. Epstein S.L., Kong W.P., Misplon J.A., et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 2005, 23:5404-5410.
12. Ferrara C., Brunker P., Suter T., Moser S., Puntener U., Umana P. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol. Bioeng. 2006, 93:851-861.
13. Ferrara C., Grau S., Jager C., et al. Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:12669-12674.
14. Fielding J.E., Grant K.A., Garcia K., Kelly H.A. Effectiveness of seasonal influenza vaccine against pandemic (H1N1) 2009 virus, Australia, 2010. Emerg. Infect. Dis. 2011, 17:1181-1187.
15. Gerhard W., Mozdzanowska K., Furchner M., Washko G., Maiese K. Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunol. Rev. 1997, 159:95-103.
16. Gong J.H., Maki G., Klingemann H.G. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994, 8:652-658.
17. Gooneratne S.L., Richard J., Lee W.S., Finzi A., Kent S.J., Parsons M.S. Slaying the Trojan horse: natural killer cells exhibit robust anti-HIV-1 antibody-dependent activation and cytolysis against allogeneic T cells. J. Virol. 2015, 89:97-109.
18. Greenberg S.B., Criswell B.S., Six H.R., Couch R.B. Lymphocyte cytotoxicity to influenza virus-infected cells: response to vaccination and virus infection. Infect. Immun. 1978, 20:640-645.
19. Hardelid P., Fleming D.M., McMenamin J., et al. Effectiveness of pandemic and seasonal influenza vaccine in preventing pandemic influenza A(H1N1)2009 infection in England and Scotland 2009-2010. Euro Surveill. Bull. Eur. Mal. Transmis. Eur. Commun. Dis. Bull. 2011, 16.
20. Hashimoto G., Wright P.F., Karzon D.T. Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells. J. Infect. Dis. 1983, 148:785-794.
21. Hashimoto G., Wright P.F., Karzon D.T. Ability of human cord blood lymphocytes to mediate antibody-dependent cellular cytotoxicity against influenza virus-infected cells. Infect. Immun. 1983, 42:214-218.
22. Hessel A., Savidis-Dacho H., Coulibaly S., et al. MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses. PLoS One 2014, 9.
23. Huber V.C., Lynch J.M., Bucher D.J., Le J., Metzger D.W. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 2001, 166:7381-7388.
24. Jegaskanda S., Job E.R., Kramski M., et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J. Immunol. 2013, 190:1837-1848.
25. Jegaskanda S., Laurie K.L., Amarasena T.H., et al. Age-associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1. J. Infect. Dis. 2013, 208:1051-1061.
26. Jegaskanda S., Weinfurter J.T., Friedrich T.C., Kent S.J. Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J. Virol. 2013, 87:5512-5522.
27. Jegaskanda S., Amarasena T.H., Laurie K.L., et al. Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques. J. Virol. 2013, 87:13706-13718.
28. Jegaskanda S., Vandenberg K., Laurie K.L., et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses. J. Infect. Dis. 2014, 210:1811-1822.
29. Jegaskanda S., Reading P.C., Kent S.J. Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine. J. Immunol. 2014, 193:469-475.
30. Jost S., Quillay H., Reardon J., et al. Changes in cytokine levels and NK cell activation associated with influenza. PLoS One 2011, 6.
31. Kim M.C., Lee Y.N., Hwang H.S., et al. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity. Vaccine 2014, 32:5824-5831.
32. Krause J.C., Tsibane T., Tumpey T.M., Huffman C.J., Basler C.F., Crowe J.E. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J. Virol. 2011, 85:10905-10908.
33. Lambe T., Carey J.B., Li Y., et al. Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1. Sci. Rep. 2013, 3:1443.
34. Lamere M.W., Moquin A., Lee F.E., et al. Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J. Virol. 2011, 85:5027-5035.
35. LaMere M.W., Lam H.T., Moquin A., et al. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J. Immunol. 2011, 186:4331-4339.
36. Laoprasopwattana K., Libraty D.H., Endy T.P., et al. Antibody-dependent cellular cytotoxicity mediated by plasma obtained before secondary dengue virus infections: potential involvement in early control of viral replication. J. Infect. Dis. 2007, 195:1108-1116.
37. Lee Y.N., Lee Y.T., Kim M.C., et al. Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination. Immunology 2014, 143:300-309.
38. Lillie P.J., Berthoud T.K., Powell T.J., et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP + M1, in humans. Clin. Infect. Dis. 2012, 55:19-25.
39. Mackett M., Smith G.L., Moss B. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J. Virol. 1984, 49:857-864.
40. Mahan A.E., Jennewein M.F., Suscovich T., et al. Antigen-specific antibody glycosylation is regulated via vaccination. PLoS Pathog. 2016, 12.
41. Mao H., Tu W., Liu Y., et al. Inhibition of human natural killer cell activity by influenza virions and hemagglutinin. J. Virol. 2010, 84:4148-4157.
42. Margine I., Hai R., Albrecht R.A., et al. H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J. Virol. 2013, 87:4728-4737.
43. Margine I., Krammer F., Hai R., et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J. Virol. 2013, 87:10435-10446.
44. Martin Mdel P., Seth S., Koutsonanos D.G., Jacob J., Compans R.W., Skountzou I. Adjuvanted influenza vaccine administered intradermally elicits robust long-term immune responses that confer protection from lethal challenge. PLoS One 2010, 5.
45. Mozdzanowska K., Maiese K., Furchner M., Gerhard W. Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 1999, 254:138-146.
46. O'Brien K.B., Morrison T.E., Dundore D.Y., Heise M.T., Schultz-Cherry S. A protective role for complement C3 protein during pandemic 2009 H1N1 and H5N1 influenza A virus infection. PLoS One 2011, 6.
47. Ohta R., Torii Y., Imai M., Kimura H., Okada N., Ito Y. Serum concentrations of complement anaphylatoxins and proinflammatory mediators in patients with 2009 H1N1 influenza. Microbiol. Immunol. 2011, 55:191-198.
48. Peiris J.S., Tu W.W., Yen H.L. A novel H1N1 virus causes the first pandemic of the 21st century. Eur. J. Immunol. 2009, 39:2946-2954.
49. Sandbulte M.R., Westgeest K.B., Gao J., et al. Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:20748-20753.
50. Shil P., Chavan S., Cherian S. Molecular basis of antigenic drift in Influenza A/H3N2 strains (1968-2007) in the light of antigenantibody interactions. Bioinformation 2011, 6:266-270.
51. Shinkawa T., Nakamura K., Yamane N., et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 2003, 278:3466-3473.
52. Smith G.L., Levin J.Z., Palese P., Moss B. Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses. Virology 1987, 160:336-345.
53. Sukeno N., Otsuki Y., Konno J., et al. Anti-nucleoprotein antibody response in influenza A infection. Tohoku J. Exp. Med. 1979, 128:241-249.
54. Terajima M., Co M.D., Cruz J., Ennis F.A. High antibody-dependent cellular cytotoxicity antibody titers to H5N1 and H7N9 avian influenza A viruses in healthy US adults and older children. J. Infect. Dis. 2015, 212:1052-1060.
55. Ulmer J.B., Donnelly J.J., Parker S.E., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259:1745-1749.
56. Vella S., Rocchi G., Resta S., Marcelli M., De Felici A. Antibody reactive in antibody-dependent cell-mediated cytotoxicity following influenza virus vaccination. J. Med. Virol. 1980, 6:203-211.
57. Vidarsson G., Dekkers G., Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front. Immunol. 2014, 5:520.
58. Virelizier J.L., Allison A.C., Oxford J.S., Schild G.C. Early presence of ribonucleoprotein antigen on surface of influenza virus-infected cells. Nature 1977, 266:52-54.
59. Vogt M.R., Dowd K.A., Engle M., et al. Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms. J. Virol. 2011, 85:11567-11580.
60. Wang T.T., Tan G.S., Hai R., et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog. 2010, 6.
61. World Health Organization Influenza (seasonal) Available at:, (Accessed February 5th). http://www.who.int/mediacentre/factsheets/fs211/en/.
62. Wraith D.C., Vessey A.E., Askonas B.A. Purified influenza virus nucleoprotein protects mice from lethal infection. J. Gen. Virol. 1987, 68(Pt 2):433-440.
63. Wren L., Parsons M.S., Isitman G., et al. Influence of cytokines on HIV-specific antibody-dependent cellular cytotoxicity activation profile of natural killer cells. PLoS One 2012, 7.
64. Xiao P., Zhao J., Patterson L.J., et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89·6P challenge in rhesus macaques. J. Virol. 2010, 84:7161-7173.
65. Yamane N., Odagiri T., Arikawa J., Ishida N. Reversed single-radial-immunodiffusion test: the method for the assay of the antibody to influenza A nucleoprotein. Tohoku J. Exp. Med. 1981, 133:245-255.
66. Yang P., Zhang L., Shi W., et al. Seroprevalence of pandemic (H1N1) 2009 influenza and effectiveness of 2010/2011 influenza vaccine during 2010/2011 season in Beijing, China. Influenza Other Respir. Viruses 2012, 6:381-388.
67. Yewdell J.W., Frank E., Gerhard W. Expression of influenza A virus internal antigens on the surface of infected P815 cells. J. Immunol. 1981, 126:1814-1819.
68. Yewdell J.W., Bennink J.R., Smith G.L., Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:1785-1789.